This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

WelChol® and Insulin in Treating Patients With Type 2 Diabetes

This study has been completed.
Information provided by (Responsible Party):
Daiichi Sankyo, Inc. Identifier:
First received: September 7, 2005
Last updated: January 16, 2012
Last verified: January 2012
The purpose of the study is to see how safe and effective and tolerable the use of WelChol® is for type 2 diabetes when added to insulin alone or in combination with other anti-diabetic drugs

Condition Intervention Phase
Type 2 Diabetes Drug: Colesevelam hydrochloride Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of WelChol® in Type 2 Diabetes With Inadequate Glycemic Control on Insulin Therapy Alone or Insulin Therapy Combination With Other Oral Anti-diabetic Agents

Resource links provided by NLM:

Further study details as provided by Daiichi Sankyo, Inc.:

Primary Outcome Measures:
  • - To assess the additional lowering of HbA1c achieved by
  • addition of WelChol® to current antidiabetic therapy

Secondary Outcome Measures:
  • To assess: the effects on fasting plasma glucose and
  • fructosamine; glycemic control response rate; effect on adiponectin; the effect on c-peptide; effect on c-reactive protein; effects on lipids and lipoproteins; the safety and tolerability of WelChol® as add-
  • on therapy to patients receiving insulin alone or with
  • other oral drugs

Estimated Enrollment: 260
Study Start Date: June 2004
Study Completion Date: December 2005
Primary Completion Date: December 2005 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ages 18 - 75 years, inclusive
  • Diagnosed with type 2 diabetes
  • Stable insulin therapy for 6 weeks
  • Stable dose of any other antidiabetic medications for 90 days
  • Hemoglobin A1c value between 7.5% to 9.5%
  • C peptide greater than 0.5 ng/mL
  • Prescribed ADA diet

Exclusion Criteria:

  • History of type 1 diabetes or ketoacidosis
  • History of pancreatitis
  • Uncontrolled hypertension
  • Allergy or toxic response to colesevelam or any of its components
  • Serum LDL-C less than 60 mg/dL
  • Serum TG greater than 500 mg/dL
  • Body mass index (BMI) greater than 45 kg/m2-
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00151749

  Show 47 Study Locations
Sponsors and Collaborators
Daiichi Sankyo, Inc.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Daiichi Sankyo, Inc. Identifier: NCT00151749     History of Changes
Other Study ID Numbers: WEL-302
Study First Received: September 7, 2005
Last Updated: January 16, 2012

Keywords provided by Daiichi Sankyo, Inc.:
Diabetes mellitus

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Colesevelam Hydrochloride
Hypoglycemic Agents
Physiological Effects of Drugs
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents processed this record on September 21, 2017